The honest bottom line comes first: Dihexa was chemically engineered to enter the brain, and preclinical rodent work supports central activity after oral dosing, but that is not the same thing as a characterized pharmacokinetic profile. Every quantitative figure in circulation traces back to either a single rodent study or a software prediction, and none of it has been measured in people. For a reader deciding how much weight to give a number attached to this molecule, the distinction between engineered intent, animal evidence, and measured human exposure is the whole question.
Dihexa produces centrally mediated effects in orally dosed rodents at low milligram-per-kilogram doses, yet no human pharmacokinetic study of the compound has been published and the only reported terminal half-life, roughly nine to thirteen days, comes from one rodent study.
The design starts from what failed. Angiotensin IV, the native hexapeptide Dihexa descends from, carries a free N-terminal amine, a free C-terminal carboxyl and a heavy hydrogen-bonding load, which makes it both an easy peptidase substrate and a poor candidate for passive movement across the tightly junctioned endothelium of the blood-brain barrier. The two hydrocarbon caps that define Dihexa were chosen to fix both problems at once, and reading the resulting property changes is what separates a real design argument from a marketing one.
The two hexanoyl caps raise Dihexa's calculated octanol/water partition coefficient to roughly 178 while pushing molecular weight just past 500, and no published study establishes whether the molecule is a substrate for P-glycoprotein or other efflux pumps that commonly cancel out lipophilicity gains.
Two very different kinds of evidence sit behind the claim that this compound reaches the brain, and they are routinely quoted as though they were one. One is a measurement of the label in brain tissue after acute carotid infusion; the other is a behavioral result in orally dosed animals that implies central activity without measuring central concentration. The gap between those two is where most of the confusion about this molecule lives.
The direct brain-exposure evidence for Dihexa rests on a single research program with a commercial interest in the molecule, in a report that has carried a journal Notice of Concern since 2021, and no unbound brain-to-plasma partition value has been published for the compound.
Metabolic stability was the first problem this design had to solve, and on this point the evidence is mechanistic rather than quantitative. The recognition handles that exopeptidases require were removed by chemistry, which explains the reported jump in survival relative to the parent peptide, but explanation is not measurement. Calling the molecule protease-proof overstates what the published record actually shows.
| Property | Angiotensin IV | Dihexa |
|---|---|---|
| N-terminus | Free alpha-amino group | Hexanoyl amide cap |
| C-terminus | Free carboxylate | 6-aminohexanoic amide |
| Exopeptidase recognition | Substrate for aminopeptidase N and A, ACE, IRAP | Classic exopeptidase routes largely closed |
| Reported half-life | Seconds to a few minutes in plasma | Several days terminal, one rodent study |
| In vitro stability value | Well characterized | Absent from the accessible record |
Capping both termini closes the aminopeptidase and carboxypeptidase routes that dismantle angiotensin IV within seconds to minutes, yet no in vitro plasma stability half-life, liver microsomal intrinsic clearance value or identified metabolite profile for Dihexa appears in the accessible peer-reviewed record.
Honest reporting on this section means saying that most of the data do not exist in public form. A conventional pharmacokinetic characterization reports peak concentration, time to peak, area under the curve, terminal half-life, volume of distribution, clearance, oral bioavailability, protein binding and mass balance of excretion, across at least two species and several dose levels. For anyone weighing a specific number quoted about this compound, the useful question is which of those nine slots is actually filled.
Of the nine parameters in a standard pharmacokinetic characterization, exactly one has been reported for Dihexa in a single rodent study, and accumulation on repeated dosing remains an open question precisely because volume of distribution and clearance were never measured alongside that long half-life.
Oral dosing carries the most support here, which is unusual enough for a peptide-derived molecule to be worth stating plainly, because the rodent studies that anchor Dihexa's reputation used the oral route and still produced central effects. Past that point the reasoning turns speculative, since no head-to-head route comparison with matched plasma and brain measurements appears in the record. Routes cannot be ranked by dose; they can only be ranked by measured exposure.
Higher plasma exposure does not translate linearly into higher brain exposure for a highly protein-bound compound whose entry is presumed passive, so a route that raises total plasma concentration may raise free brain concentration far less than the dose increase implies.
Reported effects in animals, particularly increased dendritic spine density and sustained cognitive improvement, persist for days after dosing, and that observation is often treated as settled evidence about the drug rather than the biology. It is not settled, because the single reported pharmacokinetic study describes a terminal half-life of several days rather than minutes, which leaves two competing explanations standing. Which one is correct determines whether a brain concentration measurement means anything at all.
| Criterion | Parent-compound explanation | Metabolite explanation |
|---|---|---|
| Proposed active species | Dihexa potentiating HGF signaling at c-Met | Unidentified fragment, or parent acting as partial prodrug |
| Standing in the literature | Favored by the investigators | Raised, never tested |
| Supporting evidence | Mechanistic and in vitro | No fragment isolated from dosed animals |
| Effect on reading brain data | Parent concentration is the correct assay | Parent concentration is uninformative either way |
No radiolabeled study identifying circulating and brain species and comparing their potencies has been published, so brain concentration data for Dihexa remain informative but not conclusive until the active species is pinned down.
No published human pharmacokinetic study of Dihexa exists in the peer-reviewed literature, and that single fact constrains everything else that can responsibly be said about the compound. Extrapolating rodent brain penetration to people is unreliable in both directions, because species differ in efflux transporter expression, plasma protein composition, hepatic enzyme complements and the ratio of brain volume to systemic clearance. The consequence reaches past efficacy: an unknown exposure means an unknown dose at which harm would first appear.
Because the proposed mechanism potentiates a growth factor pathway active in tissue repair and, in other contexts, in tumor biology, the absence of human pharmacokinetic and safety data is the central open question about Dihexa rather than a bookkeeping gap.
A striking share of the numerical detail attached to this compound has no traceable primary source, and the failures fall into three recognizable patterns that differ in severity. One category is invented outright, one takes a real measurement and inflates its standing, and one carries a genuine in vitro result into a claim it cannot support. Sorting a quoted number into the right category is what separates a usable figure from an anchor built on nothing.
The specific human milligram doses circulating for Dihexa trace to vendor copy and forum consensus rather than to any trial, because no human dosing study has ever been reported.
Establishing brain exposure to modern standards takes considerably more than recovering a compound from a brain homogenate, and laying out the full requirement also measures how far the current evidence sits from it. Each step below addresses a specific way a brain-penetration claim goes wrong: blood trapped in unperfused tissue, total concentration mistaken for free concentration, and an unvalidated assay reading noise as signal.
A defensible brain-exposure package for Dihexa would report an unbound brain-to-plasma partition coefficient from equilibrium dialysis, an efflux transporter substrate screen, and a validated liquid chromatography tandem mass spectrometry assay with a stated lower limit of quantification, none of which has been published.
Educational use only. This article describes what the published scientific and clinical literature reports about Dihexa. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
